Regulatory Updates
🇺🇸 FDA Page 25FDA news and analysis for pharmaceutical BD, investment, and market access · 12 articles on this page
Track global pharma regulatory policy changes, FDA, EMA, and other agency guidelines impacting drug development and market access. Stay ahead.
Showing 289–300 of 373 articles
Will 2026 Be Pharma’s M&A Breakout Year? Market Analysis
Takeda and Novartis Layoffs: Implications for Pharma Industry
Palvella's Pivotal Rare-Disease Data and Financial Outlook
FDA to Consider Lifting Restrictions on Compounded Peptides
FDA Alert: Key Updates on Pulmonology Drug Approvals
Regeneron Pharma Stock Surges: Fresh Institutional Buying Insights
FDA's Bayesian Methodology: A Game Changer for Drug Development
SELLAS Nears Key AML Data: Insights for Investors and BD Teams
Palvella's Nasdaq Uplisting: Implications for Rare Disease Development
Top 10 Biopharma M&A Deals of 2025: Market Analysis
Navigating Ghost Approval in Heart Transplant Medications
AstraZeneca Secures FDA Approval for Hypertension Drug